

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 November 2023 (23.11.2023)



(10) International Publication Number
WO 2023/222122 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 19/06 (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/CN2023/095342

(22) International Filing Date:

19 May 2023 (19.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/094043

20 May 2022 (20.05.2022) CN

(71) Applicant: **JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.** [CN/CN]; Suite 401, Building C31, Biomedical Industry Park, 218 Xinghu Street, Suzhou Industrial Park, China (Jiangsu) Pilot Free Trade Zone-Suzhou Area, Suzhou, Jiangsu 215123 (CN).


(72) Inventors: **SHI, Dongfang**; Suite 401, Building C31, Biomedical Industry Park, 218 Xinghu Street, Suzhou Industrial Park, China (Jiangsu) Pilot Free Trade Zone-Suzhou Area, Suzhou, Jiangsu 215123 (CN). **FU, Changjin**; Suite

401, Building C31, Biomedical Industry Park, 218 Xinghu Street, Suzhou Industrial Park, China (Jiangsu) Pilot Free Trade Zone-Suzhou Area, Suzhou, Jiangsu 215123 (CN). **YANG, Yan**; Suite 401, Building C31, Biomedical Industry Park, 218 Xinghu Street, Suzhou Industrial Park, China (Jiangsu) Pilot Free Trade Zone-Suzhou Area, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **NANJING SITUO INTELLECTUAL PROPERTY AGENCY (GP)**; Room 905, Floor 9, B1 Block, Jing Feng Le Chuang Center, No.68 Hua Chuang Road, Jiangbei New Area, Nanjing, Jiangsu 211899 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT



Compound I




FIG. 1

(57) Abstract: Crystalline forms of Compound I, active on URAT1, were prepared and characterized: Also provided are methods of using the crystalline forms.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))